4-氯-6-硝基-2-(1-哌嗪)喹啉 | 437708-76-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-6-硝基-2-(1-哌嗪)喹啉
• 英文名称: 4-Chloro-6-nitro-2-piperazin-1-yl-quinoline
• 英文别名: 4-Chloro-6-nitro-2-(piperazin-1-YL)quinoline；4-chloro-6-nitro-2-piperazin-1-ylquinoline
• CAS: 437708-76-4
• 化学式: C₁₃H₁₃ClN₄O₂
• 分子量: 292.725
• InChiKey: HADJVDJPSUSVPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氯-6-硝基-2-(1-哌嗪)喹啉 、 碘甲烷 在 氢氧化钾 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以72%的产率得到4-Chloro-2-(4-methyl-piperazin-1-yl)-6-nitro-quinoline
  参考文献：
  名称：

  Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 4: 3-Alkyl-4-halo-6-nitroquipazines

  摘要：

  On the basis of the structure activity relationship (SAR) of 4-chloro-6-nitroquipazine (K-i = 0.03 nM) and 3-fluoropropyl-6-nitroquipazine (K-i = 0.32 nM), 3-alkyl-4-halo-6-nitroquipazines were synthesized and tested for their potential abilities in vitro to displace [H-3]citalopram binding to the rat cortical membranes. Binding affinities of 3h and 4d were K-i = 2.70 +/- 0.32 and 2.23 +/- 0.46 nM. respectively. The syntheses of 3-alkyl-4-halo-6-nitroquipazine. their in vitro binding affinitics. and the SAR of C3, C4 position in 6-nitroquipazine are described. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.05.031
• 作为产物：
  描述：

  3-(4-硝基苯胺基)-3-氧代丙酸乙酯 在 PPA 、 三氯氧磷 作用下， 反应 5.0h， 生成 4-氯-6-硝基-2-(1-哌嗪)喹啉
  参考文献：
  名称：

  Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 4: 3-Alkyl-4-halo-6-nitroquipazines

  摘要：

  On the basis of the structure activity relationship (SAR) of 4-chloro-6-nitroquipazine (K-i = 0.03 nM) and 3-fluoropropyl-6-nitroquipazine (K-i = 0.32 nM), 3-alkyl-4-halo-6-nitroquipazines were synthesized and tested for their potential abilities in vitro to displace [H-3]citalopram binding to the rat cortical membranes. Binding affinities of 3h and 4d were K-i = 2.70 +/- 0.32 and 2.23 +/- 0.46 nM. respectively. The syntheses of 3-alkyl-4-halo-6-nitroquipazine. their in vitro binding affinitics. and the SAR of C3, C4 position in 6-nitroquipazine are described. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.05.031

文献信息

• Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
  申请人：Chi Dae-Yoon

  公开号：US20050165006A1

  公开（公告）日：2005-07-28

  Novel quinoline derivatives were prepared and evaluated their pharmaceutical activities. The quinoline derivatives according to the present invention effectively bind serotonin transporter (SERT) which is called serotonin reuptake site. Serotonin is one of the neurotransmitter and the lack of its concentration in synapse cause the depression. The quinoline derivatives in this invention can interrupt reuptake of serotonin into presynaptic neuron resulting the increasement of concentration of serotonin in synapse as well as stimulating the signal through the binding with serotonin recepter. Thus, they can be used for the prevention and treatment of mental disorder, especially depression, caused by the deficiency of serotonin concentration in synapse.

  通过本发明制备了新型喹啉衍生物，并评估了它们的药物活性。本发明的喹啉衍生物能够有效地结合血清素转运体（SERT），也称为血清素再摄取位点。血清素是一种神经递质，如果突触中缺乏其浓度，则会导致抑郁症。本发明中的喹啉衍生物可以中断血清素重新摄取到突触前神经元中，从而增加突触中血清素的浓度，并通过与血清素受体结合刺激信号。因此，它们可以用于预防和治疗由突触中血清素浓度不足引起的心理障碍，特别是抑郁症。
• Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. part 2: 4-Substituted 6-nitroquipazines
  作者：Byoung Se Lee、Soyoung Chu、Bon-Su Lee、Dae Yoon Chi、Yun Seon Song、Changbae Jin

  DOI：10.1016/s0960-894x(02)00028-8

  日期：2002.3

  Eleven 4-substituted derivatives of 6-nitroquipazine were synthesized and evaluated for their abilities to displace [H-3]citalopram binding to the rat cortical synaptic membranes. Among them, 4-chloro-6-nitroquipazine was shown to possess the highest binding affinity (K-i - 0.03 nM) which was approximately 6 times higher than that of 6-nitroquipazine (K-i = 0.17 nM) itself. In this paper, we describe the syntheses of 4-substituted 6-nitroquipazine derivatives, the results of corresponding biological evaluation and the SAR study. (C) 2002 Elsevier Science Ltd. All rights reserved.
• [EN] QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] DERIVES DE QUINOLINE, PREPARATIONS DE CES DERIVES ET COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES DERIVES
  申请人：CHEMON INC

  公开号：WO2003082286A1

  公开（公告）日：2003-10-09

  Novel quinoline derivatives were prepared and evaluated their pharmaceutical activities. The quinoline derivatives according to the present invention effectively bind serotonin transporter (SERT) which is called serotonin reuptake site. Serotonin is one of the neurotransmitter and the lack of its concentration in synapse cause the depression. The quinoline derivatives in this invention can interrupt reuptake of serotonin into presynaptic neuron resulting the increasement of concentration of serotonin in synapse as well as stimulating the signal through the binding with serotonin recepter. Thus, they can be used for the prevention and treatment of mental disorder, especially depression, caused by the deficiency of serotonin concentration in synapse.
• Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 4: 3-Alkyl-4-halo-6-nitroquipazines
  作者：Byung Seok Moon、Byoung Se Lee、Dae Yoon Chi

  DOI：10.1016/j.bmc.2005.05.031

  日期：2005.8

  On the basis of the structure activity relationship (SAR) of 4-chloro-6-nitroquipazine (K-i = 0.03 nM) and 3-fluoropropyl-6-nitroquipazine (K-i = 0.32 nM), 3-alkyl-4-halo-6-nitroquipazines were synthesized and tested for their potential abilities in vitro to displace [H-3]citalopram binding to the rat cortical membranes. Binding affinities of 3h and 4d were K-i = 2.70 +/- 0.32 and 2.23 +/- 0.46 nM. respectively. The syntheses of 3-alkyl-4-halo-6-nitroquipazine. their in vitro binding affinitics. and the SAR of C3, C4 position in 6-nitroquipazine are described. (c) 2005 Elsevier Ltd. All rights reserved.